Real‑world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain

• Javier Puente ^[6] ; Alvaro Pinto ^[1] ; Maria José Mendez Vidal ^[7] ; Xavier García del Muro ^[2] ; Pablo Maroto ^[3] ; Sergio Vazquez ^[4] ; Raquel Luque Caro ^[5] ; Urbano Anido ^[8] ; Torsten Strunz McKendry ^[9] ; Jose Montes ^[10] ; Aurora Ortiz Nuñez ^[9] ; Judit González Portela ^[9] ; Anil Upadhyay ^[9] ; Daniel Castellano ^[11]
  1. [1] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  2. [2] Universitat de Barcelona

     Universitat de Barcelona

     Barcelona, España

     
  3. [3] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  4. [4] Hospital Universitario Lucus Augusti

     Hospital Universitario Lucus Augusti

     Lugo, España

     
  5. [5] Hospital Universitario Virgen de las Nieves

     Hospital Universitario Virgen de las Nieves

     Granada, España

     
  6. [6] Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Calle del Prof Martín Lagos, S/N, 28040 Madrid, Spain
  7. [7] Medical Oncology Department, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Cordoba, Spain
  8. [8] Servicio de Oncología Médica, Hospital Universitario de Santiago, Santiago, Spain
  9. [9] Astellas Pharma Europe Ltd, Addlestone, Surrey, UK
  10. [10] Effice Research, Madrid, Spain
  11. [11] Medical Oncology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 27, Nº. 5, 2025, págs. 2232-2240
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose Real-world evidence on locally advanced or metastatic urothelial carcinoma (la/mUC) management in Spain is limited. This study describes patient characteristics, treatment patterns, survival, and health care resource utilization (HCRU) in this population.

    Methods/patients This retrospective observational study included all adults with a frst diagnosis/record of la/mUC (index date) from January 2015 to June 2020 at nine university hospitals in Spain. Data were collected up to December 31, 2020 (end of study), death, or loss to follow-up. Patient characteristics, treatment patterns, median overall survival (OS) and progression-free survival (PFS) from index date (Kaplan–Meier estimates), and disease-specifc HCRU were described.

    Results Among 829 patients, median age at diagnosis was 71 years; 70.2% had≥1 comorbidity, and 52.5% were eligible for cisplatin. Median follow-up was 12.7 months. Most (84.7%) patients received frst-line systemic treatment; of these, 46.9% (n=329) received second-line and 16.6% (n=116) received third-line therapy. Chemotherapy was the most common treatment in all lines of therapy, followed by programmed cell death protein 1/ligand 1 inhibitors. Median (95% confdence interval) OS and PFS were 18.8 (17.5–21.5) and 9.9 (8.9–10.5) months, respectively. Most patients required≥1 outpatient visit (71.8%), inpatient admission (56.6%), or emergency department visit (56.5%).

    Conclusions Therapeutic patterns were consistent with Spanish guideline recommendations. Chemotherapy had a role in first-line treatment of la/mUC in Spain during the study period. However, the disease burden remains high, and new first-line treatments recommended in the latest European guidelines should be made available to patients in Spain.